PD-L1 can be expressed in tumor cells as a result of genetic modifications including PTEN loss, EGFR mutations, MYC overexpression, mutations in the PI3K/AKT signaling pathway and PDJ amplification [39]. This evidence concerns the gene CD274 and neoplasm.